@phdthesis{Schlaberg2004, author = {Schlaberg, Robert}, title = {Neuroprotektiver Effekt von Ribavirin bei Borna Disease Virus infizierten Lewis-Ratten}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-9772}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2004}, abstract = {Die Infektion mit dem Borna Disease Virus (BDV) ruft bei einem weiten Spektrum von Warmbl{\"u}tern ein teilweise progredientes, immunmediiertes neurologisches Syndrom hervor. BDV zeichnet sich durch ein einzelstr{\"a}ngiges RNA Genom negativer Polarit{\"a}t, einen ausgepr{\"a}gten Neurotropismus und einen nicht-lytischen Replikationszyklus aus, der in viraler Persistenz m{\"u}ndet. In vitro Experimente zeigten k{\"u}rzlich einen virostatischen Effekt des Guanosinanalogs Ribavirin gegen{\"u}ber BDV. Ziel der vorliegenden Studie war es, den therapeutischen Nutzen einer intrathekalen Ribavirinapplikation bei akuter Bornascher Erkrankung (BD) im Rattenmodell zu untersuchen. Toxikologische und pharmakokinetische Studien ergaben eine maximal vertr{\"a}gliche t{\"a}gliche Dosis von 2,5 mg/kg KG. Drei Wochen nach intranasaler Virusinokulation wurde Ribavirin in einer Dosis von 0, 1,25 und 2,5 mg/kg KG/Tag f{\"u}r 7 Tage intrathekal appliziert. Hierdurch gelang es, die klinische Symptomatik akuter BD dosisabh{\"a}ngig zu reduzieren. Die Bestimmung der Konzentration viraler RNA, Proteine, sowie infekti{\"o}ser Partikel in zentralnerv{\"o}sem Gewebe ergab jedoch keine signifikante Reduktion. Anschließende immunhistologische Untersuchungen konnten eine quantitative Reduktion von T-Lymphozyten und Mikrogliazellen in Hirnparenchym behandelter Tiere nachweisen. Sowohl CD4+, als auch CD8+ T-Lymphozyten sind wesentlich an der progressiven Neurodestruktion im Rahmen von BD beteiligt. Auch f{\"u}r Mikrogliazellen wird eine kausale Beteiligung an der Pathogenese von BD postuliert. Der klinisch protektive Effekt der zentralen Ribavirinapplikation scheint in dem vorliegenden Modell nicht auf eine Inhibition der Virusreplikation, sondern auf die Suppression der neuropathogenen Immunantwort des Wirtsorganismus zur{\"u}ckzuf{\"u}hren zu sein. Wie in anderen Studien wiederholt beschrieben, konnte virale RNA im Blut infizierter Lewis-Ratten detektiert werden. Die Vir{\"a}mie bei hochdosiert behandelten Tieren ist deutlich ausgepr{\"a}gter. Diese Beobachtung ist vermutlich durch eine systemische Infektion unter insuffizienter Immunkontrolle zu erkl{\"a}ren. Hieraus ergeben sich auch Implikationen f{\"u}r die diagnostische Nutzbarkeit des peripheren Nukleins{\"a}urenachweises zur Erkennung von BDV Infektionen. Die intrathekale Ribavirinapplikation ist der erste therapeutische Ansatz f{\"u}r BD, der zu einer Linderung des akuten Krankheitsbildes ohne gleichzeitige verst{\"a}rkte Virusreplikation f{\"u}hrt.}, language = {de} } @phdthesis{Korte2007, author = {Korte, Gabriele}, title = {Flavonoid-induzierte Cytotoxizit{\"a}t, Neuroprotektion und Immunmodulation im Zellmodell}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-26627}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2007}, abstract = {Flavonoide sind weitverbreitete sekund{\"a}re Pflanzeninhaltsstoffe. Ihr Beitrag zur Pr{\"a}vention von chronischen Erkrankungen wird zu großen Teilen auf immunmodulatorische und neuroprotektive Effekte zur{\"u}ckgef{\"u}hrt. Eine Voraussetzung f{\"u}r die Nutzung dieser Eigenschaften der Flavonoide stellt die Erfassung cytotoxischer Effekte dar. Mit Ausnahme von Xanthohumol und Quercetin ist f{\"u}r alle im Rahmen der vorliegenden Arbeit untersuchten Flavonoide, Hispidulin, Baicalein, Scutellarein, Hesperetin, Chrysin, Apigenin, Naringenin, Catechin, Pelargonidinchlorid und EMD 21388, sowohl in T-Zellen (Jurkat) als auch in neuronalen (SK-N-SH)-Zellen nach 24-st{\"u}ndiger Inkubation eine geringgradige Cytotoxizit{\"a}t festzuhalten. F{\"u}r Xanthohumol bzw. Quercetin wird ein halbmaximaler Verlust der Zellvitalit{\"a}t je nach Modell in Konzentrationen von 33-45 µM bzw. 118-208 µM erreicht. Der weiterf{\"u}hrenden Charakterisierung (zVAD, DNA-Laddering) ist zu entnehmen, dass die zellul{\"a}ren Ver{\"a}nderungen substanzabh{\"a}ngig differieren und sowohl nekrotische Mechanismen (Xanthohumol) als auch apoptotische Vorg{\"a}nge (Quercetin) einschließen. Eine erh{\"o}hte Lipidperoxidation im oberen Dosisbereich l{\"a}sst dar{\"u}ber hinaus auf eine Beteiligung von oxidativem Stress an den von Xanthohumol-induzierten nekrotischen Prozessen schließen. Eine positive Einflussnahme auf die Zellvitalit{\"a}t durch Antioxidantien wie GSH und NAC l{\"a}sst des Weiteren vermuten, dass die erfassten Flavonoid-induzierten Prozesse jeweils sensitiv zum Redoxzustand der Zelle sind. W{\"a}hrend die Effekte von Xanthohumol auch in anderen Zellmodellen (HL-60) nachweisbar bleiben, verh{\"a}lt sich Quercetin nicht durchgehend vitalit{\"a}tsmindernd. Unterschiede zwischen den Testsubstanzen bestehen auch hinsichtlich antioxidativer Effekte. Das Eliminieren freier Radikale z{\"a}hlt zu den wichtigsten Mechanismen, die bei Flavonoid-vermittelter Neuroprotektion eine Rolle spielen. Insgesamt sind alle diesbez{\"u}glich untersuchten Substanzen als starke Superoxidanionen-Radikalf{\"a}nger einzustufen. Im Co-Inkubationsversuch zeigt Scutellarein den st{\"a}rksten Effekt, gefolgt von Quercetin, Hispidulin und Xanthohumol. Im Pr{\"a}-Inkubations-Versuchsmodell liegen in der Reihenfolge ihrer Effektst{\"a}rken Xanthohumol vor Quercetin, Hispidulin und schließlich Scutellarein. Die modellabh{\"a}ngigen Konstanten k{\"o}nnen, unter Beteiligung einer passiven Diffusion der hydrophoben Flavonoidaglykone, auf eine substanzgebundene Membranpermeabilit{\"a}t zur{\"u}ckzuf{\"u}hren sein. Das antioxidative Potential der Flavonoide resultiert u.a. aus einer komplexen Einflußnahme auf die Genexpression in der Zelle. In der vorliegenden Arbeit sind anhand von cDNA-Arrays f{\"u}r mehrere Vertreter {\"u}bereinstimmend Wechselwirkungen mit Genen der zellul{\"a}ren Abwehr dargestellt. Demnach f{\"u}hren Scutellarein, Hispidulin, Quercetin und Xanthohumol zu einer deutlich reduzierten Expressionsst{\"a}rke von STK4, CHD4, ARHGDIB, IL16, ISG20, PFN1 und SOD2. Unter den Flavonoid-induzierten Ver{\"a}nderungen ragen die Effekte auf ADAR1 heraus, dessen Genexpression von Scutellarein bis auf ein 0,1-faches der Referenzwerte reduziert wird. Gleichsinnige Auswirkungen von Scutellarein auf die Expression von ADAR1-Protein in Western Blots unterstreichen diese Interaktion und legen nahe, dass ADAR-vermittelte enzymatische Deaminierungen durch Flavonoide moduliert werden k{\"o}nnen. Diese Beobachtung wird erg{\"a}nzt durch den nachgewiesenen Effekt von Flavonoiden auf die Expression einer Reihe weiterer Gene (ADAR2, APOBEC3B, APOBEC3C, APOBEC3F und APOBEC3G), die analoge posttranskriptionale Mechanismen steuern und gleichermaßen in Immunabwehr und Neuroprotektion eingebunden sind. Zu den wichtigsten Substraten von ADAR z{\"a}hlen Glutamatrezeptoren. Erwartungsgem{\"a}ß ist nach der Einwirkung von Scutellarein auf humane Zellen, die Glutamatrezeptoren exprimieren, ein R{\"u}ckgang der Deaminierung im Bereich der Glutamatrezeptoruntereinheit GluR 2 zu verzeichnen (Q/R-Position). Dem entspricht in elektrophysiologischen Modellen eine gesteigerte Ca2+-Permeabilit{\"a}t der jeweiligen Ionenkan{\"a}le und eine ver{\"a}nderte neuronale Exzitabilit{\"a}t. Hieraus ergibt sich ein breites Spektrum zus{\"a}tzlicher Optionen f{\"u}r die Induktion von gesundheitsrelevanten Flavonoidfunktionen in der Zelle. So spielt die Modulation von Deaminierungen zugleich eine entscheidende Rolle im Vermehrungszyklus viraler Erreger. Die Annahme einer m{\"o}glichen antiviralen Qualit{\"a}t von Scutellarein wird durch ein HBV-Infektionsmodell anhand drei Parameter der Virusreplikation (Virus-DNA-Konzentration, HBs- bzw. HBe-Antigenproduktion) best{\"a}tigt. Offen bleibt auch nach ausf{\"u}hrlicher Pr{\"u}fung, ob der deutliche antivirale Effekt als das Produkt von Flavonoid-induzierten Ver{\"a}nderungen der Deaminierungsraten oder als Folge eines Effekts auf die virale Polymerase zu interpretieren ist. Die hier dargestellten Wirkmechanismen leisten einen Beitrag zum Verst{\"a}ndnis der Bedeutung von Flavonoiden f{\"u}r neue Anwendungen in Neuroprotektion und Immunabwehr.}, subject = {Flavonoide}, language = {de} } @phdthesis{Dreiseitel2011, author = {Dreiseitel, Andrea}, title = {In vitro bioactivities of dietary anthocyanins and proanthocyanidins: implications for bioavailability, neuroprotection and safety}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-57550}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2011}, abstract = {Over the past decades, awareness has increased of multiple health-promoting effects of diets rich in anthocyanins and proanthocyanidins and, specifically, of these compounds' potential for conferring neuroprotection. The present study compiles evidence obtained in vitro that expands our understanding of anthocyanin and proanthocyanidin functionalities at multiple levels. Firstly, anthocyanin and anthocyanidin bioavailability was addressed using a combination of ATPase assays, dye extrusion assays and vesicular transport assays. This approach highlights the contribution made by efflux transporters MDR1 and BCRP to the absorption of berry polyphenols and to their distribution to target tissues including the central nervous system. All test compounds interacted with the BCRP transporter in vitro, seven emerged as potential BCRP substrates and 12 as potential inhibitors of BCRP. Two anthocyanidins, malvidin and petunidin, exhibited bimodal activities, serving as BCRP substrates at low micromolar concentrations and, at higher concentrations, as BCRP inhibitors. Effects on MDR1, in contrast, were weak, as only aglycones exerted mild inhibitory activity in the high micromolar range. Distinct affinities of several anthocyanins and the respective aglycones for BCRP suggest that they may be actively transported out of endothelia. Agents that interfere with BCRP activity are therefore likely to facilitate crossing of the intestinal and blood-brain barriers and to augment anthocyanin bioavailability. Secondly, novel modes of action were sought to rationalize berry polyphenols' direct modulation of neuronal transmission as opposed to their non-specific antioxidant activities. The candidate effectors include cellular monoamine oxidases (MAO) A and B, hypoxia inducible factor (HIF), the proteasome, and phospholipase A2 (PLA2). Elevated MAO activity has long been implicated in the etiology of depression, anxiety and neurodegenerative illness. MAO inhibiting compounds may thus hold promise in the prevention of behavioral symptoms and cognitive decline. For both MAO isoforms, inhibitory effects of anthocyanins and anthocyanidins are illustrated by IC50 values in the low micromolar range whereas proanthocyanidins and phenolic metabolites were less effective inhibitors. Kinetic analyses, performed with cyanidin and cyanidin-3-glucoside, indicated a competitive interaction of cyanidin in terms of MAO A, plus a mixed competitive and non-competitive mode of interaction of cyanidin in terms of MAO B as well as of cyanidin-3-glucoside with respect to both enzyme isoforms. Thus MAO inhibition by anthocyanins and their aglycones in vitro lends support to central nervous functionalities of diets rich in berry polyphenols and opens new opportunities in the prevention of neuronal pathologies. Effects on HIF expression were examined to assess candidate compounds' role in enhancing cellular resistance to oxidative stress. By inducing a dose-dependent increase in HIF expression, delphinidin may initiate a variety of cellular survival processes that are inhibited by free iron. This finding argues in favor of iron-chelating properties as a further means of mediating neuroprotection. Other inducers of HIF expression in neuroblastoma cells included gallic acid, cyanidin and bilberry extract, all of which may modulate HIF-dependent transcription of downstream genes.}, subject = {Anthocyane}, language = {en} } @article{BoltzeKleinschnitzReymannetal.2012, author = {Boltze, Johannes and Kleinschnitz, Christoph and Reymann, Klaus G. and Reiser, Georg and Wagner, Daniel-Christoph and Kranz, Alexander and Michalski, Dominik}, title = {Neurovascular pathophysiology in cerebral ischemia, dementia and the ageing brain - current trends in basic, translational and clinical research}, series = {Experimental \& Translational Stroke Medicine}, volume = {4}, journal = {Experimental \& Translational Stroke Medicine}, number = {14}, doi = {doi:10.1186/2040-7378-4-14}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-126679}, year = {2012}, abstract = {The 7th International Symposium on Neuroprotection and Neurorepair was held from May 2nd to May 5th, 2012 in Potsdam, Germany. The symposium, which directly continues the successful Magdeburg meeting series, attracted over 330 colleagues from 29 countries to discuss recent findings and advances in the field. The focus of the 2012 symposium was widened from stroke and traumatic brain injury to neurodegenerative diseases, notably dementia, and more generally the ageing brain. Thereby, emphasis was given on neurovascular aspects of neurodegeneration and stroke including the blood-brain barrier, recent findings regarding the pathomechanism of Alzheimer's disease, and brain imaging approaches. In addition, neurobiochemical aspects of neuroprotection, the role of astrogliosis, the clinical progress of cell-based approaches as well as translational hurdles and opportunities were discussed in-depth. This review summarizes some of the most stimulating discussions and reports from the meeting.}, language = {en} } @article{GerlachMaetzlerBroichetal.2012, author = {Gerlach, Manfred and Maetzler, Walter and Broich, Karl and Hampel, Harald and Rems, Lucas and Reum, Torsten and Riederer, Peter and St{\"a}ffler, Albrecht and Streffer, Johannes and Berg, Daniela}, title = {Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics}, series = {Journal of Neural Transmission}, volume = {119}, journal = {Journal of Neural Transmission}, number = {1}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125375}, pages = {39-52}, year = {2012}, abstract = {Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson's disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies.}, language = {en} } @article{MinnerupSutherlandBuchanetal.2012, author = {Minnerup, Jens and Sutherland, Brad A. and Buchan, Alastair M. and Kleinschnitz, Christoph}, title = {Neuroprotection for Stroke: Current Status and Future Perspectives}, series = {International Journal of Molecular Science}, volume = {13}, journal = {International Journal of Molecular Science}, number = {9}, doi = {10.3390/ijms130911753}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134730}, pages = {11753-11772}, year = {2012}, abstract = {Neuroprotection aims to prevent salvageable neurons from dying. Despite showing efficacy in experimental stroke studies, the concept of neuroprotection has failed in clinical trials. Reasons for the translational difficulties include a lack of methodological agreement between preclinical and clinical studies and the heterogeneity of stroke in humans compared to homogeneous strokes in animal models. Even when the international recommendations for preclinical stroke research, the Stroke Academic Industry Roundtable (STAIR) criteria, were followed, we have still seen limited success in the clinic, examples being NXY-059 and haematopoietic growth factors which fulfilled nearly all the STAIR criteria. However, there are a number of neuroprotective treatments under investigation in clinical trials such as hypothermia and ebselen. Moreover, promising neuroprotective treatments based on a deeper understanding of the complex pathophysiology of ischemic stroke such as inhibitors of NADPH oxidases and PSD-95 are currently evaluated in preclinical studies. Further concepts to improve translation include the investigation of neuroprotectants in multicenter preclinical Phase III-type studies, improved animal models, and close alignment between clinical trial and preclinical methodologies. Future successful translation will require both new concepts for preclinical testing and innovative approaches based on mechanistic insights into the ischemic cascade.}, language = {en} } @article{BauneKonradGrotegerdetal.2012, author = {Baune, Bernhard T. and Konrad, Carsten and Grotegerd, Dominik and Suslow, Thomas and Birosova, Eva and Ohrmann, Patricia and Bauer, Jochen and Arolt, Volker and Heindel, Walter and Domschke, Katharina and Sch{\"o}ning, Sonja and Rauch, Astrid V. and Uhlmann, Christina and Kugel, Harald and Dannlowski, Udo}, title = {Interleukin-6 gene (IL-6): a possible role in brain morphology in the healthy adult brain}, series = {Journal of Neuroinflammation}, volume = {9}, journal = {Journal of Neuroinflammation}, number = {125}, doi = {10.1186/1742-2094-9-125}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-130804}, year = {2012}, abstract = {Background: Cytokines such as interleukin 6 (IL-6) have been implicated in dual functions in neuropsychiatric disorders. Little is known about the genetic predisposition to neurodegenerative and neuroproliferative properties of cytokine genes. In this study the potential dual role of several IL-6 polymorphisms in brain morphology is investigated. Methodology: In a large sample of healthy individuals (N = 303), associations between genetic variants of IL-6 (rs1800795; rs1800796, rs2069833, rs2069840) and brain volume (gray matter volume) were analyzed using voxel-based morphometry (VBM). Selection of single nucleotide polymorphisms (SNPs) followed a tagging SNP approach (e. g., Stampa algorigthm), yielding a capture 97.08\% of the variation in the IL-6 gene using four tagging SNPs. Principal findings/results In a whole-brain analysis, the polymorphism rs1800795 (-174 C/G) showed a strong main effect of genotype (43 CC vs. 150 CG vs. 100 GG; x = 24, y = -10, z = -15; F(2,286) = 8.54, p(uncorrected) = 0.0002; p(AlphaSim-corrected) = 0.002; cluster size k = 577) within the right hippocampus head. Homozygous carriers of the G-allele had significantly larger hippocampus gray matter volumes compared to heterozygous subjects. None of the other investigated SNPs showed a significant association with grey matter volume in whole-brain analyses. Conclusions/significance: These findings suggest a possible neuroprotective role of the G-allele of the SNP rs1800795 on hippocampal volumes. Studies on the role of this SNP in psychiatric populations and especially in those with an affected hippocampus (e.g., by maltreatment, stress) are warranted.}, language = {en} } @article{CoxLimpensVlesvandenHoveetal.2014, author = {Cox-Limpens, Kimberly E. M. and Vles, Johan S. H. and van den Hove, Daniel L. A. and Zimmermann, Luc Ji and Gavilanes, Antonio W. D.}, title = {Fetal asphyctic preconditioning alters the transcriptional response to perinatal asphyxia}, series = {BMC Neuroscience}, volume = {15}, journal = {BMC Neuroscience}, doi = {10.1186/1471-2202-15-67}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-116185}, pages = {67}, year = {2014}, abstract = {Background: Genomic reprogramming is thought to be, at least in part, responsible for the protective effect of brain preconditioning. Unraveling mechanisms of this endogenous neuroprotection, activated by preconditioning, is an important step towards new clinical strategies for treating asphyctic neonates. Therefore, we investigated whole-genome transcriptional changes in the brain of rats which underwent perinatal asphyxia (PA), and rats where PA was preceded by fetal asphyctic preconditioning (FAPA). Offspring were sacrificed 6 h and 96 h after birth, and whole-genome transcription was investigated using the Affymetrix Gene1.0ST chip. Microarray data were analyzed with the Bioconductor Limma package. In addition to univariate analysis, we performed Gene Set Enrichment Analysis (GSEA) in order to derive results with maximum biological relevance. Results: We observed minimal, 25\% or less, overlap of differentially regulated transcripts across different experimental groups which leads us to conclude that the transcriptional phenotype of these groups is largely unique. In both the PA and FAPA group we observe an upregulation of transcripts involved in cellular stress. Contrastingly, transcripts with a function in the cell nucleus were mostly downregulated in PA animals, while we see considerable upregulation in the FAPA group. Furthermore, we observed that histone deacetylases (HDACs) are exclusively regulated in FAPA animals. Conclusions: This study is the first to investigate whole-genome transcription in the neonatal brain after PA alone, and after perinatal asphyxia preceded by preconditioning (FAPA). We describe several genes/pathways, such as ubiquitination and proteolysis, which were not previously linked to preconditioning-induced neuroprotection. Furthermore, we observed that the majority of upregulated genes in preconditioned animals have a function in the cell nucleus, including several epigenetic players such as HDACs, which suggests that epigenetic mechanisms are likely to play a role in preconditioning-induced neuroprotection.}, language = {en} } @article{RottlaenderKuerten2015, author = {Rottlaender, Andrea and Kuerten, Stefanie}, title = {Stepchild or prodigy? Neuroprotection in multiple sclerosis (MS) research}, series = {International Journal of Molecular Sciences}, volume = {16}, journal = {International Journal of Molecular Sciences}, doi = {10.3390/ijms160714850}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148416}, pages = {14850-14865}, year = {2015}, abstract = {Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) and characterized by the infiltration of immune cells, demyelination and axonal loss. Loss of axons and nerve fiber pathology are widely accepted as correlates of neurological disability. Hence, it is surprising that the development of neuroprotective therapies has been neglected for a long time. A reason for this could be the diversity of the underlying mechanisms, complex changes in nerve fiber pathology and the absence of biomarkers and tools to quantify neuroregenerative processes. Present therapeutic strategies are aimed at modulating or suppressing the immune response, but do not primarily attenuate axonal pathology. Yet, target-oriented neuroprotective strategies are essential for the treatment of MS, especially as severe damage of nerve fibers mostly occurs in the course of disease progression and cannot be impeded by immune modulatory drugs. This review shall depict the need for neuroprotective strategies and elucidate difficulties and opportunities.}, language = {en} } @phdthesis{Schampel2017, author = {Schampel, Andrea}, title = {Beneficial therapeutic effects of the L-type calcium channel antagonist nimodipine in experimental autoimmune encephalomyelitis - an animal model for multiple sclerosis}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148952}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2017}, abstract = {Multiple sclerosis (MS) is the most prevalent neurological disease of the central nervous system (CNS) in young adults and is characterized by inflammation, demyelination and axonal pathology that result in multiple neurological and cognitive deficits. The focus of MS research remains on modulating the immune response, but common therapeutic strategies are only effective in slowing down disease progression and attenuating the symptoms; they cannot cure the disease. Developing an option to prevent neurodegeneration early on would be a valuable addition to the current standard of care for MS. Based on our results we suggest that application of nimodipine could be an effective way to target both neuroinflammation and neurodegeneration. We performed detailed analyses of neurodegeneration in experimental autoimmune encephalomyelitis (EAE), an animal model of MS, and in in vitro experiments regarding the effect of the clinically well-established L-type calcium channel antagonist nimodipine. Nimodipine treatment attenuated the course of EAE and spinal cord histopathology. Furthermore, it promoted remyelination. The latter could be due to the protective effect on oligodendrocytes and oligodendrocyte precursor cells (OPCs) we observed in response to nimodipine treatment. To our surprise, we detected calcium channel-independent effects on microglia, resulting in apoptosis. These effects were cell type-specific and independent of microglia polarization. Apoptosis was accompanied by decreased levels of nitric oxide (NO) and inducible NO synthase (iNOS) in cell culture as well as decreased iNOS expression and reactive oxygen species (ROS) activity in EAE. Overall, application of nimodipine seems to generate a favorable environment for regenerative processes and could therefore be a novel treatment option for MS, combining immunomodulatory effects while promoting neuroregeneration.}, subject = {Nimodipin}, language = {en} }